P240001 The PearlMatrix P-15 Peptide Enhanced Bone Graft has achieved a significant milestone with its FDA approval, marking a pivotal moment in spinal fusion technology. This innovative bone graft, developed by Cerapedics, is recognized as the first and only bone growth accelerator specifically proven to accelerate lumbar fusion2025年7月8日—PearlMatrix Bone Graft received U.S. FDA premarket approval in June 2025and is the first and only bone growth accelerator proven to accelerate .... The FDA premarket approval (PMA) signifies its clearance for use in specific spinal fusion procedures, underscoring its safety and efficacy as determined by rigorous regulatory review.
At the heart of PearlMatrix lies the proprietary P-15 Osteogenic Cell Binding Peptide. This peptide is designed to mimic natural bone growth factors, actively promoting osteoblast (bone-forming cell) attachment and proliferation. This targeted action is crucial for enhancing the speed and success rate of bone fusion, a critical component in spinal surgeries aimed at stabilizing vertebrae. The P-15 peptide is synthesized, offering a controlled and consistent biological stimulus that differentiates it from traditional bone graft materials.
The path to FDA approval for medical devices like PearlMatrix is extensive. Cerapedics first secured Breakthrough Device designation for PearlMatrix in 2021, a designation granted to devices that offer a significant advantage over existing approved options for life-threatening or irreversibly debilitating diseasesFDA Approves Cerapedics' PearlMatrix Bone Graft. This was followed by the pivotal FDA premarket approval (PMA) in June 2025, with the official Date of FDA Notice of Approval being June 18, 2025Cerapedics Treats First U.S. Patient with PearlMatrix™ .... This PMA approval allows PearlMatrix to be marketed as a bone growth accelerator for lumbar fusion.
Further advancements include expanded indications for use. In January 2026, Cerapedics announced FDA approval to broaden the labeling for PearlMatrix P-15, permitting its use in conjunction with various interbody fusion cages, including those made from titanium alloy and PEEK/titanium, that are themselves cleared by the FDA for use in the lumbosacral spine. This expansion increases the versatility and applicability of PearlMatrix in a wider range of surgical scenarios, including single-level TLIF (transforaminal lumbar interbody fusion) proceduresCerapedics.
PearlMatrix P-15 is primarily indicated for use in spinal fusion procedures, particularly in the lumbar region, to promote the fusion of bone. Its unique peptide technology aims to accelerate the natural bone healing process, potentially leading to:
* Faster Fusion Rates: By actively stimulating bone cell activity, PearlMatrix can help achieve solid bone fusion more quickly than some conventional methods.“We are pleased to announceFDA approval of an IDE supplementresulting in a reduction of the total number of patients required to be enrolled in our IDE study ...
* Improved Patient Outcomes: Accelerated fusion can translate to reduced patient recovery times, less post-operative pain, and a quicker return to normal activities.2025年7月9日—PearlMatrix is the first and only bone graft approved through the PMA pathwaythat is specifically proven to FDA premarket approval (PMA).
* Enhanced Surgical Options: Its compatibility with various spinal fusion devices and instrumentation offers surgeons greater flexibility in tailoring treatment plans.
The clinical evidence supporting PearlMatrix includes studies demonstrating its ability to accelerate lumbar fusion.Expanded Indications for Cerapedics' PearlMatrix P-15 For instance, Cerapedics announced the publication of 24-month data in the journal *Spine*, further substantiating the long-term efficacy of their P-15 peptide-powered products.
PearlMatrix P-15 stands out in the crowded field of bone graft materials due to its peptide-based mechanism and its specific FDA approval as a bone growth accelerator for lumbar fusion. Unlike allografts (human bone) or synthetic grafts that primarily provide a scaffold, PearlMatrix actively signals the body to build bone.PearlMatrix™ P-15 Peptide Enhanced Bone Graft, ...Date of FDA Notice of Approval: June 18, 2025. Breakthrough Device: Granted breakthrough device status on ... Cerapedics also has another PMA-approved product utilizing the P-15 peptide, positioning them as a leader in peptide-enhanced bone grafting solutions.
It is important to note that while PearlMatrix has received widespread approval and positive clinical attention, there have been instances of recalls. For example, a Class 2 Device Recall was issued in January 2026 concerning an incorrect expiration date on some PearlMatrix P15 Peptide Enhanced Bone Graft units, highlighting the importance of diligent post-market surveillance and adherence to labeling requirementsPremarket Approval (PMA) - FDA.
In conclusion, the FDA approval of the PearlMatrix P-15 Peptide Enhanced Bone Graft represents a significant advancement in orthopedic and neurosurgical interventions for spinal fusion. Its innovative peptide technology, coupled with robust regulatory clearance and expanding clinical applications, positions it as a valuable tool for surgeons seeking to optimize fusion outcomes for their patients.
Join the newsletter to receive news, updates, new products and freebies in your inbox.